Cavitation Technologies, Inc. (CVAT) announced on October 9, 2026, that it has entered into definitive tender offer agreements with BrightFlixx Finance (Luxembourg) S.A. to acquire all outstanding shares of the company and its subsidiary, Alchemy Beverages Inc. The agreements replace previous agreements with European Guarantee Services S.à r.l., which were terminated on October 8, 2026.
Under the terms of the agreements, BrightFlixx intends to commence a cash tender offer for all outstanding shares of Cavitation Technologies common stock for an aggregate purchase price of $35 million, less the company's outstanding liabilities. The offer price will be determined by dividing the $35 million by the total number of shares outstanding at the close of a Record Date, which will be set at 45 business days after the offer begins.
Similarly, BrightFlixx will offer to purchase all outstanding shares of Alchemy common stock for an aggregate purchase price of $7 million, less Alchemy's outstanding liabilities, using the same calculation method. The aggregate proposed cash consideration for both transactions is $42 million.
The tender offers are subject to several conditions, including the tender of at least 90% of the outstanding shares of each company, receipt of regulatory approval or a no-objection determination from the Committee on Foreign Investment in the United States (CFIUS), and the concurrent consummation of the other tender offer. The offer period is initially scheduled to expire 60 business days after commencement, with an extension of at least 30 business days provided after the final offer price is publicly announced.
The Company holds a 17% equity stake in Alchemy Beverages, which is why the tender offer for Alchemy is being disclosed. As of the filing date, neither tender offer has commenced. The Company expects to file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC once the offers begin.
